Scholars Central

ArticlePublished 2011

Xolair: A New Monoclonal Drug Anti-IgE Antibody for the Treatment of Allergic Asthma

Authors: Monica Di Domenico, Mario Polverino, Concetta De Rosa, Vilma Ricci, Angelica Bisogno, Anna Capasso

Biomedical Research

Volume 22 · Issue 1

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Xolair is a monoclonal antibody that binds the Cε3 domain of IgEs, inducing a conforma-tional change of the immunoglobulin, a concealment of FcεRI and FcεRII receptors binding sites, thus precluding binding by IgEs and therefore stopping the release of inflammation mediators. Xolair is indicated as add-on therapy to improve/control asthma in adult and adolescent patients (12 years of age and above) suffering from severe persistent allergic asthma. The aim of our work was to evaluate the Xolair efficacy in the asthma treatment. Six patients (4 men and 2 women aged 30 to 60 years) were selected for the treatment with Xolair. Previously, they were treated with high doses of long-acting β2-agonists and inhaled corticosteroids, but they were not able to control their illness despite the assumption of such drugs. Xolair was administered for 32 weeks in addition to the traditional asthma therapy. Xolair dosage was calculated according to their weight and their IgE levels (IU/ml). The the-rapeutic response was evaluated according to the GETE (Global Evaluation of Treatment Effectiveness) scale. The persistence of the response was defined, instead, by the number of patients continuing to respond positively to the treatment between the 16th and the 32nd week. 4 of 6 patients concluded the study. Patient number 2, in fact, had a body weight higher than 150 kg, so it was impossible to establish the necessary drug dosage. Patient number 6, instead, still had too high IgE values at his fourth checkup. Patient number 1 was fit in the efficacy level 2 (Good) at the 16th week, while at the 32nd week, he was in the level 1 (Excellent). Patient number 3 was at an efficacy level 1 yet from the 16th week, and that level was confirmed at the 32nd. In patient number 4, as well in that number 1, an increase of treatment efficacy was proved with a passage from level 2 to level 1. Finally, for the patient number 5, the efficacy level was Good both at the 16th and at the 32nd week (level 2). The re-sults obtained were positive for all patients and not only the persistence of a therapeutic re-sponse was confirmed, but in some cases there was an improvement of efficacy. Therefore, we can conclude that Xolair, administrated as an additional therapy, strongly improved the severe persistent IgE-mediated asthma. The anti-IgE Xolair treatment reduces the asthma frequency, also, it improved the patient life quality, by inducing positive effects on symp-toms and pulmonary function.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Similar by topic

More from this journal

The newest in Biomedical Research.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalBiomedical Research
  • SubjectPathology & Lab Medicine
  • BylineArticles whose byline prints “Monica Di Domenico”
  • BylineArticles whose byline prints “Mario Polverino”
  • BylineArticles whose byline prints “Concetta De Rosa”
  • BylineArticles whose byline prints “Vilma Ricci”
  • BylineArticles whose byline prints “Angelica Bisogno”
  • BylineArticles whose byline prints “Anna Capasso”

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels